Interest Expense of ALNYLAM PHARMACEUTICALS, INC. from 31 Dec 2018 to 31 Mar 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of the cost of borrowed funds accounted for as interest expense.
Summary
ALNYLAM PHARMACEUTICALS, INC. quarterly and annual Interest Expense in USD history and change rate from 31 Dec 2018 to 31 Mar 2024.
  • ALNYLAM PHARMACEUTICALS, INC. Interest Expense for the quarter ending 31 Mar 2024 was $35,253,000, a 22% increase year-over-year.
  • ALNYLAM PHARMACEUTICALS, INC. Interest Expense for the twelve months ending 31 Mar 2024 was $127,519,000, a 11% decline year-over-year.
  • ALNYLAM PHARMACEUTICALS, INC. annual Interest Expense for 2023 was $121,221,000, a 22% decline from 2022.
  • ALNYLAM PHARMACEUTICALS, INC. annual Interest Expense for 2022 was $155,968,000, a 9.1% increase from 2021.
  • ALNYLAM PHARMACEUTICALS, INC. annual Interest Expense for 2021 was $143,021,000, a 69% increase from 2020.
Source SEC data
View on sec.gov
Interest Expense, Trailing 12 Months (USD)
Interest Expense, Quarterly (USD)
Interest Expense, YoY Quarterly Change (%)
Interest Expense, Annual (USD)
Interest Expense, YoY Annual Change (%)

ALNYLAM PHARMACEUTICALS, INC. Quarterly Interest Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2024 $127,519,000 $35,253,000 +$6,298,000 +22% 01 Jan 2024 31 Mar 2024 10-Q 02 May 2024 2024 Q1
Q4 2023 $121,221,000 $31,338,000 +$1,425,000 +4.8% 01 Oct 2023 31 Dec 2023 10-K 15 Feb 2024 2023 FY
Q3 2023 $119,796,000 $30,893,000 -$10,191,000 -25% 01 Jul 2023 30 Sep 2023 10-Q 02 Nov 2023 2023 Q3
Q2 2023 $129,987,000 $30,035,000 -$12,574,000 -30% 01 Apr 2023 30 Jun 2023 10-Q 03 Aug 2023 2023 Q2
Q1 2023 $142,561,000 $28,955,000 -$13,407,000 -32% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024 2024 Q1
Q4 2022 $155,968,000 $29,913,000 -$6,903,000 -19% 01 Oct 2022 31 Dec 2022 10-K 15 Feb 2024 2023 FY
Q3 2022 $162,871,000 $41,084,000 +$810,000 +2% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $162,061,000 $42,609,000 +$9,193,000 +28% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $152,868,000 $42,362,000 +$9,847,000 +30% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $143,021,000 $36,816,000 +$8,299,000 +29% 01 Oct 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
Q3 2021 $134,722,000 $40,274,000 +$11,543,000 +40% 01 Jul 2021 30 Sep 2021 10-Q 27 Oct 2022 2022 Q3
Q2 2021 $123,179,000 $33,416,000 +$6,168,000 +23% 01 Apr 2021 30 Jun 2021 10-Q 28 Jul 2022 2022 Q2
Q1 2021 $117,011,000 $32,515,000 +$32,515,000 01 Jan 2021 31 Mar 2021 10-Q 28 Apr 2022 2022 Q1
Q4 2020 $84,496,000 $28,517,000 01 Oct 2020 31 Dec 2020 10-K 23 Feb 2023 2022 FY
Q3 2020 $28,731,000 +$28,731,000 01 Jul 2020 30 Sep 2020 10-Q 28 Oct 2021 2021 Q3
Q2 2020 $27,248,000 +$27,248,000 01 Apr 2020 30 Jun 2020 10-Q 03 Aug 2021 2021 Q2
Q1 2020 $0 01 Jan 2020 31 Mar 2020 10-Q 29 Apr 2021 2021 Q1
Q3 2019 $0 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $0 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2

ALNYLAM PHARMACEUTICALS, INC. Annual Interest Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $121,221,000 -$34,747,000 -22% 01 Jan 2023 31 Dec 2023 10-K 15 Feb 2024 2023 FY
2022 $155,968,000 +$12,947,000 +9.1% 01 Jan 2022 31 Dec 2022 10-K 15 Feb 2024 2023 FY
2021 $143,021,000 +$58,525,000 +69% 01 Jan 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
2020 $84,496,000 +$84,496,000 01 Jan 2020 31 Dec 2020 10-K 23 Feb 2023 2022 FY
2019 $0 $0 01 Jan 2019 31 Dec 2019 10-K 10 Feb 2022 2021 FY
2018 $0 01 Jan 2018 31 Dec 2018 10-K 11 Feb 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.